ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Mapping the genetic landscape of suicide risk: Insights from genomic SEM.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genetic basis of traits associated with suicide risk remains poorly understood. We applied genomic structural equation modeling and integrated multiple post-genome-wide association study (GWAS) analysis strategies to identify potential causal single-nucleotide polymorphisms independent of known high-risk suicide syndrome GWAS variants, identifying four genome-wide-significant, putatively causal loci and six putatively causal genes. Additionally, we applied multiple transcriptome-wide association study (TWAS) methods at the tissue and cellular levels to fine-map susceptibility genes. Subsequently, we analyzed the key regulatory elements driving their expression. Next, we assessed genetic pleiotropy by evaluating genetic correlations between high-risk suicide syndrome and over one hundred common diseases. Furthermore, we constructed a polygenic risk score (PRS) from the summary statistics to quantify each chromosome's contribution to the associated genetic risk. Our study systematically delineated the overall genetic architecture of high-risk suicide syndrome through a GWAS of this previously unmeasured latent phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.